A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS (BAFF) Antibody, in Subjects With Primary Sjogren's Syndrome.

Trial Profile

A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS (BAFF) Antibody, in Subjects With Primary Sjogren's Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs Belimumab (Primary)
  • Indications Sjogren's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BELISS
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Feb 2016 Follow-up results (n=13) published in the Clinical and Experimental Rheumatology.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top